247 related articles for article (PubMed ID: 37716913)
1. TAZ facilitates breast tumor growth by promoting an immune-suppressive tumor microenvironment.
Gershoni A; Hassin O; Nataraj NB; Baruch S; Avioz-Seligman A; Pirona AC; Fellus-Alyagor L; Meir Salame T; Mukherjee S; Mallel G; Yarden Y; Aylon Y; Oren M
Mol Oncol; 2023 Dec; 17(12):2675-2693. PubMed ID: 37716913
[TBL] [Abstract][Full Text] [Related]
2. Loss-of-function of the hippo transducer TAZ reduces mammary tumor growth through a myeloid-derived suppressor cell-dependent mechanism.
Shen H; Zhang Y; Kramer ED; Katsuta E; Wan Y; Chen Y; Wang J; Zhang Y; Matsuzaki J; Frangou C; Abrams SI; Zhang J
Cancer Gene Ther; 2022 Nov; 29(11):1791-1800. PubMed ID: 35840667
[TBL] [Abstract][Full Text] [Related]
3. Hippo-TAZ signaling is the master regulator of the onset of triple-negative basal-like breast cancers.
Soyama H; Nishio M; Otani J; Sakuma T; Takao S; Hara S; Masuda T; Mimori K; Toyokuni S; Lydon JP; Nakao K; Nishina H; Fukumoto T; Maehama T; Suzuki A
Proc Natl Acad Sci U S A; 2022 Jul; 119(29):e2123134119. PubMed ID: 35858357
[TBL] [Abstract][Full Text] [Related]
4. YAP and TAZ are transcriptional co-activators of AP-1 proteins and STAT3 during breast cellular transformation.
He L; Pratt H; Gao M; Wei F; Weng Z; Struhl K
Elife; 2021 Aug; 10():. PubMed ID: 34463254
[TBL] [Abstract][Full Text] [Related]
5. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
[TBL] [Abstract][Full Text] [Related]
6. Non-secreting pituitary tumours characterised by enhanced expression of YAP/TAZ.
Xekouki P; Lodge EJ; Matschke J; Santambrogio A; Apps JR; Sharif A; Jacques TS; Aylwin S; Prevot V; Li R; Flitsch J; Bornstein SR; Theodoropoulou M; Andoniadou CL
Endocr Relat Cancer; 2019 Jan; 26(1):215-225. PubMed ID: 30139767
[TBL] [Abstract][Full Text] [Related]
7. SKI activates the Hippo pathway via LIMD1 to inhibit cardiac fibroblast activation.
Landry NM; Rattan SG; Filomeno KL; Meier TW; Meier SC; Foran SJ; Meier CF; Koleini N; Fandrich RR; Kardami E; Duhamel TA; Dixon IMC
Basic Res Cardiol; 2021 Apr; 116(1):25. PubMed ID: 33847835
[TBL] [Abstract][Full Text] [Related]
8. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy.
Zhu J; Wu T; Lin Q
Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351
[TBL] [Abstract][Full Text] [Related]
9. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
Jang JW; Kim MK; Bae SC
Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
[TBL] [Abstract][Full Text] [Related]
10. The Hippo effector TAZ (WWTR1) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma.
Mohamed A; Sun C; De Mello V; Selfe J; Missiaglia E; Shipley J; Murray GI; Zammit PS; Wackerhage H
J Pathol; 2016 Sep; 240(1):3-14. PubMed ID: 27184927
[TBL] [Abstract][Full Text] [Related]
11. TAZ maintains telomere length in TNBC cells by mediating Rad51C expression.
Yang L; Wang B; Jiao X; Zhou C; Chen S; Gao X; Sun W; Song S; Li J; Liu J; Wang Y; Liu P
Breast Cancer Res; 2021 Sep; 23(1):89. PubMed ID: 34488828
[TBL] [Abstract][Full Text] [Related]
12. TAZ Protein Accumulation Is Negatively Regulated by YAP Abundance in Mammalian Cells.
Finch-Edmondson ML; Strauss RP; Passman AM; Sudol M; Yeoh GC; Callus BA
J Biol Chem; 2015 Nov; 290(46):27928-38. PubMed ID: 26432639
[TBL] [Abstract][Full Text] [Related]
13. The oncogenic roles and clinical implications of YAP/TAZ in breast cancer.
Luo J; Zou H; Guo Y; Tong T; Chen Y; Xiao Y; Pan Y; Li P
Br J Cancer; 2023 May; 128(9):1611-1624. PubMed ID: 36759723
[TBL] [Abstract][Full Text] [Related]
14. An indispensable role of TAZ in anoikis resistance promoted by OTUB1 deubiquitinating enzyme in basal-like triple-negative breast cancer cells.
Nakagawa H; Higurashi M; Ishikawa F; Mori K; Shibanuma M
Biochem Biophys Res Commun; 2023 Mar; 649():1-9. PubMed ID: 36738577
[TBL] [Abstract][Full Text] [Related]
15. The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ.
Edwards DN; Ngwa VM; Wang S; Shiuan E; Brantley-Sieders DM; Kim LC; Reynolds AB; Chen J
Sci Signal; 2017 Dec; 10(508):. PubMed ID: 29208682
[TBL] [Abstract][Full Text] [Related]
16. PYK2 negatively regulates the Hippo pathway in TNBC by stabilizing TAZ protein.
Kedan A; Verma N; Saroha A; Shreberk-Shaked M; Müller AK; Nair NU; Lev S
Cell Death Dis; 2018 Sep; 9(10):985. PubMed ID: 30250159
[TBL] [Abstract][Full Text] [Related]
17. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ).
Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B
J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650
[TBL] [Abstract][Full Text] [Related]
18. Hippo/YAP signaling choreographs the tumor immune microenvironment to promote triple negative breast cancer progression via TAZ/IL-34 axis.
Wang Z; Wang F; Ding XY; Li TE; Wang HY; Gao YH; Wang WJ; Liu YF; Chen XS; Shen KW
Cancer Lett; 2022 Feb; 527():174-190. PubMed ID: 34929335
[TBL] [Abstract][Full Text] [Related]
19. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis.
Liu F; Lagares D; Choi KM; Stopfer L; Marinković A; Vrbanac V; Probst CK; Hiemer SE; Sisson TH; Horowitz JC; Rosas IO; Fredenburgh LE; Feghali-Bostwick C; Varelas X; Tager AM; Tschumperlin DJ
Am J Physiol Lung Cell Mol Physiol; 2015 Feb; 308(4):L344-57. PubMed ID: 25502501
[TBL] [Abstract][Full Text] [Related]
20. Synaptopodin-2 suppresses metastasis of triple-negative breast cancer via inhibition of YAP/TAZ activity.
Liu J; Ye L; Li Q; Wu X; Wang B; Ouyang Y; Yuan Z; Li J; Lin C
J Pathol; 2018 Jan; 244(1):71-83. PubMed ID: 28991374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]